Multidentate Terephthalamidate and Hydroxypyridonate Ligands: Towards New Orally Active Chelators

REFERENCES

• Andrews NC. Disorders of iron metabolism. N Eng J Med. 1999;341(26):1986–1995.
   PubMed Web of Science ®Google Scholar
• Durbin PW, Lauriston S. Taylor lecture: The quest for therapeutic actinide chelators. Health Phys. 2008;95(5):465–492.
   PubMed Web of Science ®Google Scholar
• Scott LE, Orvig C. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev. 2009;109:4885–4910.
   PubMed Web of Science ®Google Scholar
• Hershko C. Oral iron chelators: new opportunities and new dilemmas. Haematologica. 2006;91(10):1307–1312.
   PubMed Web of Science ®Google Scholar
• Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev. 2005;(4):CD004450 (Review).
   Google Scholar
• Durbin PW. Actinides in animals and man. In: Morss LR, Edelstein NM, Fuger J, Eds. The Chemistry of the Actinide and Transactinide Elements. Amsterdam: Springer Verlag. 2006:3339–3440.
   Google Scholar
• Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2007;(3):CD004849 (Review).
   Google Scholar
• Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436–3441.
   PubMed Web of Science ®Google Scholar
• Porter JB. Deferasirox: an effective once-daily orally active iron chelator. Drugs Today (Barc). 2006;42(10):623–637.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Response to the Letter to the Editor. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008;32(6):608–615.
   PubMed Web of Science ®Google Scholar
• Hider RC, Zhou T. The design of orally active iron chelators. Ann NY Acad Sci. 2005;1054:141–154.
   PubMed Web of Science ®Google Scholar
• Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57(4):547–583.
   PubMed Web of Science ®Google Scholar
• Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C. Irc011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture. Blood. 1997;90(10):4180–4187.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.
   PubMed Web of Science ®Google Scholar
• Abergel RJ, Raymond KN. Synthesis and thermodynamic evaluation of mixed hexadentate linear iron chelators containing hydroxypyridinone and terephthalamide units. Inorg Chem. 2006;45(9):3622–3631.
   PubMed Web of Science ®Google Scholar
• Abergel RJ, Raymond KN. Terephthalamide-containing ligands: fast removal of iron from transferrin. J Biol Inorg Chem. 2008;13(2):229–240.
   PubMed Web of Science ®Google Scholar
• Jurchen KMC, Raymond KN. A bidentate terephthalamide ligand, tammeg, as an entry into terephthalamide-containing therapeutic iron chelating agents. Inorg Chem. 2006;45(6):2438–2447.
   PubMed Web of Science ®Google Scholar
• Jurchen KMC, Raymond KN. Terephtalamide-containing analogs of tren-me-3,2-hopo. Inorg Chem. 2006;45(3):1078–1090.
   PubMedGoogle Scholar
• Abergel RJ, Durbin PW, Kullgren B, . Biomimetic actinide chelators: An update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Phys. 2010;99(3):401–407.
   PubMed Web of Science ®Google Scholar
• Durbin PW, Jeung N, Kullgren B, Clemons GK. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys. 1992;63(4):427–442.
   PubMed Web of Science ®Google Scholar
• Durbin PW, Kullgren B, Xu J, Raymond KN. In vivo chelation of Am(III), Pu(IV), Np(V), and U(VI) in mice by TREN(Me-3,2-HOPO). Radiat Prot Dosim. 1994; 53(1–4):305–309.
   Web of Science ®Google Scholar
• Durbin PW, Kullgren B, Xu J, Raymond KN. Multidentate hydroxypyridonate ligands for Pu(IV) chelation in vivo: Comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. Int J Rad Biol. 2000;76(2):199–214.
   PubMed Web of Science ®Google Scholar
• Raymond KN, Telford JR. Siderophore-mediated iron transport in microbes. In: Kessissoglou DP, Ed. Bioinorganic Chemistry An Inorganic Perspective of Life. Dordrecht: Kluwer Academic Publishers. 1995:25–37.
   Google Scholar
• Evers A, Hancock RD, Martell AE, Motekaitis RJ. Metal-ion recognition in ligands with negatively charged oxygen donor groups – complexation of Fe(III), Ga(III), In(III), Al(III), and other highly charged metal-ions. Inorg Chem. 1989;28(11):2189–2195.
   Web of Science ®Google Scholar
• Heinz U, Hegetschweiler K, Acklin P, Faller B, Lattmann R, Schnebli HP. 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]- benzoic acid: a novel efficient and selective iron(III) complexing agent. Angew Chem Int Ed. 1999;38(17):2568–2570.
   PubMed Web of Science ®Google Scholar
• Ma R, Reibenspies JJ, Martell AE. Stabilities of 1,2-diethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal-ions. Inorg Chim Acta. 1994;223(1–2):21–29.
   Web of Science ®Google Scholar
• Mack C. Essential of Statistics For Scientists and Technologists. New York: Plenum Press, 1967.
   Google Scholar